MTOR and renal cell adenocarcinoma: The Spanish Oncology Genitourinary Group (SOGUG) presented the results of an observational prospective study collecting samples from 77 RCC patients treated with mTOR inhibitors everolimus or temsirolimus (79 and 21% of cases, respectively) (37).